High-risk Cytomegalovirus in Heart Transplant: How Can We Improve?

Background: Cytomegalovirus (CMV) infection is associated with worse outcomes after heart transplant (HT). CMV mismatch (donor positive, recipient negative serology, D+/R-) increases the risk of infection. Guidelines recommend 3 to 6 months of antiviral prophylaxis in these patients.

Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.

Background And Aims: Baseline cardiovascular toxicity risk stratification is critical in cardio-oncology. The Heart Failure Association (HFA) and International Cardio-Oncology Society (ICOS) score aims to assess this risk but lacks real-life validation. This study validates the HFA-ICOS score for anthracycline-induced cardiovascular toxicity.

Coronary Sinus Reducer Transfemoral Extraction After Intraprocedural Device Migration to the Pulmonary Artery.

Coronary sinus reducer migration during implantation is an unusual complication with no standard bailout strategy and to the best of our knowledge there is no description of migration to the pulmonary artery. A mother-and-child technique during implantation could be the safest way to avoid this complication.